Advertisement

Conservative/Medical Treatment of CVM

  • Iris Baumgartner
  • Byung-Boong Lee
Chapter

Abstract

Patients with congenital vascular malformations (CVM) span a wide variety of manifestations. The complexity of CVM often requires difficult and, sometimes, invasive treatment. Conservative and medical management is focused on prevention of symptoms and complications.

References

  1. 1.
    Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P, Huang Y, Laredo J, Loose DA, Markovic J, Mattassi R, Parsi K, Rabe E, Rosenblatt M, Shortell C, Stillo F, Vaghi M, Villavicencio L, Zamboni P. Diagnosis and treatment of venous malformations consensus document of the international union of phlebology (IUP): updated 2013. Int Angiol. 2015;34(2):97–149.PubMedGoogle Scholar
  2. 2.
    Fahrni JO, Cho E-YN, Engelberger RP, Baumgartner I, von Känel R. Quality of life in patients with congenital vascular malformations. J Vasc Surg Venous Lym Dis. 2014;2:46–51.CrossRefGoogle Scholar
  3. 3.
    Lee BB, Baumgartner I, Berlien HP, Bianchini G, Burrows P, Do YS, Ivancev K, Kool LS, Laredo J, Loose DA, Lopez-Gutierrez JC, Mattassi R, Parsi K, Rimon U, Rosenblatt M, Shortell C, Simkin R, Stillo F, Villavicencio L, Yakes W. Consensus document of the international union of angiology (IUA) – 2013 Current concepts on the management of arterio-venous malformations. Int Angiol. 2013;32(1):9–36.PubMedGoogle Scholar
  4. 4.
    Oduber CE, van Beers EJ, Bresser P, van der Horst CM, Meijers JC, Gerdes VE. Venous thromboembolism and prothrombotic parameters in Klippel-Trenaunay syndrome. Neth J Med. 2013;71(5):246–52.PubMedGoogle Scholar
  5. 5.
    Dompmartin A, Acher A, Thibon P, Tourbach S, Hermans C, Deneys V, Pocock B, Lequerrec A, Labbé D, Barrellier MT, Vanwijck R, Vikkula M, Boon L. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008;144(7):873–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mazoyer E, Enjolras O, Laurian C, Houdart E, Drouet L. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol. 2002;24(4):243–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Mazoyer E, Enjolras O, Bisdorff A, Perdu J, Wassef M, Drouet L. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol. 2008;144(7):861–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Mattassi R, Vaghi M. Management of the marginal vein: current issues. Phlebology. 2007;22(6):283–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee BB, Laredo J: Chapter 7. Coagulation issue in venous malformation and its management. pp 93–127. Clinical handbook of management of antithrombotic & thrombolytic therapy. GHR Rao, E. Kalodiki, WA Leong, J Fareed (eds). 2014, Kontentworx, New DelhiGoogle Scholar
  10. 10.
    Chlebicki MP, Oh CC. Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment. Curr Infect Dis Rep. 2014;16(9):422–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011;57:321–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Burrows PE, Mulliken JB, Fishman SJ, Klement GL, Folkman J. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child. J Craniofac Surg. 2009;20(Suppl 1):597–602.CrossRefPubMedGoogle Scholar
  14. 14.
    Adam Z, Pour L, Krejcí M, Pourová E, Synek O, Zahradová L, Navrátil M, Mechl M, Nebeský T, Neubauer J, Feit J, Vokurková J, Král Z, Bednarík O, Slampa P, Dolezalová H, Hájek R, Mayer J. Successful treatment of angiomatosis with thalidomide and interferon alpha. A description of five cases and overview of treatment of angiomatosis and proliferating hemangiomas. Vnitr Lek. 2010;56(8):810–23.PubMedGoogle Scholar
  15. 15.
    Bauditz J, Lochs H. Angiogenesis and vascular mal- formations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol. 2007;13:5979–84.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16(4):420–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Tan HH, Ge ZZ, Chen HM, Gao YJ. Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy. J Dig Dis. 2013;14(3):153–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001;24:1050–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med. 2012;366(4):384–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Danial C, Tichy AL, Tariq U, Swetman GL, Khuu P, Leung TH, Benjamin L, Teng J, Vasanawala SS, Lane AT. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. J Am Acad Dermatol. 2014;22(14):01119.Google Scholar
  21. 21.
    Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Reinglas J, Ramphal R, Bromwich M. The successful management of diffuse lymphangiomatosis using sirolimus: a case report. Laryngoscope. 2011;121(9):1851–4.PubMedGoogle Scholar
  24. 24.
    Adams D, Hammill A, Trenor C. Phase II clinical trial of Sirolimus for the treatment of complicated vascular anomalies; initial results. Proceedings 20th international workshop on vascular anomales, Melbourne, 2014, p. 20–1.Google Scholar
  25. 25.
    Yuksekkaya H, Ozbek O, Keser M, Toy H. Blue rubber bleb nevus syndrome: successful treatment with sirolimus. Pediatrics. 2012;129(4):e1080–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Junquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM, Saperas E, Piqué JM, Malagelada JR. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121:1073–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther. 1999;13:1429–36.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Clinical and Interventional AngiologySwiss Cardiovascular Center, University Hospital BernBernSwitzerland
  2. 2.Center for the Lymphedema and Vascular MalformationsGeorge Washington UniversityWashington, DCUSA
  3. 3.Uniformed ServicesUniversity of the Health SciencesBethesdaUSA

Personalised recommendations